Education and Training
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: brentuximab vedotin
- drug: nivolumab
Eligibility
Inclusion Criteria:
- Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
chemotherapy for the treatment of classical Hodgkin lymphoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
- Previously treated with brentuximab vedotin, immune-oncology agents, or received an
allogeneic or autologous stem cell transplant
- Documented history of a cerebral vascular event
- History of another invasive malignancy that has not been in remission for at least 3
years
- History of progressive multifocal leukoencephalopathy (PML)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting